Interleukin Genetics To Host Second Quarter 2006 Financial Results Conference Call On August 10
INTERLEUKIN GENETICS TO HOST SECOND QUARTER 2006 FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 10
Conference Call Scheduled for 8:30 AM EST – August 10, 2006
WALTHAM, MA – August 4, 2006 – Interleukin Genetics, Inc. (AMEX: ILI) today announced that it will release its second quarter financial results on Wednesday, August 9 after the market closes. The Company’s management will host the conference call at 8:30 AM EST on Thursday, August 10 to review Interleukin’s financial results and provide a general company update.
Conference Call Details
To access the live call on August 10, 2006 at 8:30 AM EST, dial (877) 502-9272 (domestic) or (913) 981-5581 (international). The call will also be available live via webcast at www.ilgenetics.com.
Replay access of the teleconference will be available for two weeks following the call by calling (719) 457-0820 (domestic) or (888) 203-1112 (international). The passcode for the replay is 4134319. The webcast will be archived following the call at www.ilgenetics.com
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing and commercializing personalized health products. The company uses its proprietary technology to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin Genetics has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment and general nutrition assessment, and its current development programs focus on osteoporosis and weight management. Interleukin expects that these programs will also lead to products that will personalize the selection of nutritional and therapeutic products and enable the managed care industry to improve patient care and better allocate resources. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to construct a DNA testing laboratory, our ability to complete all of our key milestones with regard to Alticor programs, our ability to make progress in advancing our core technologies and our ability to launch new commercial products and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Janet Perry
(781) 398-0700
08/10/2006